|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BECN1-knockout impairs tumor growth, migration and invasion by suppressing the cell cycle and partially suppressing the epithelial-mesenchymal transition of human triple-negative breast cancer cells.
|
30015871 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors from patients with lymph node metastasis exhibited significantly lower Beclin 1 mRNA and protein expression levels compared with tumors from patients without lymph node involvement (P<0.05).
|
29163702 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We took BECN1, a core gene in autophagy performing a tumor inhibitory effect, as a starting point.
|
28401970 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Beclin1 is an essential autophagy regulator and a haploinsufficient tumor-suppressor.
|
28479384 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Regulation of the Tumor-Suppressor BECLIN 1 by Distinct Ubiquitination Cascades.
|
29186924 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Beclin-1 and LC3-II was associated with lymph node metastasis of PTC (P<0.05), but had no association with age, gender, tumor size, tumor number and Tumor-Node-Metastasis stage (P>0.05).
|
28693184 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Remarkably, LY3023414's anti-tumor activity was further augmented against the Beclin-1-silenced U251MG tumors.
|
29228741 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results demonstrated that Beclin-1 expression in gastric carcinoma tissue was significantly associated with the tumor, node, metastasis stage and tumor invasion status.
|
29163705 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TW-37's anti-tumor activity was further potentiated against Beclin-1-silenced HCT-116 tumors.
|
29065135 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results demonstrate that Beclin‑1 acts as a tumour suppressor in the development or progression of OTSCC and that Beclin‑1 may represent a novel prognostic marker for patients with OTSCC.
|
27356955 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Via these biologic functions, Beclin 1 contributes to both tumor suppression and tumor progression.
|
26357854 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNF216 promoted CRC cell proliferation and migration in vitro and in vivo, largely by enhancing proteasomal degradation of BECN1, a key autophagy regulator and tumor suppressor.
|
27203674 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated that at least some tumor suppressor functions of Beclin 1 were mediated through posttranscriptional regulation of ZEB1 via AUF1 in thyroid cancers.
|
27683118 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry was used to investigate the expression and prognostic significance of Beclin-1 in CRC, while the weak expression of Beclin-1 in normal tissue was used as the basis for assessing tumors (control group).
|
27173217 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a significant inverse correlation between loss of Beclin-1 with histologic grade and tumor stage supporting a tumor suppressive role for Beclin-1.
|
27696537 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As a critical mediator, BECN1 influences the onset and advance of autophagy and several studies have pointed to the BECN1 recurrent allelic deletion and expression variation in a broad range of tumors.
|
26765290 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, these three genes are also considered tumor suppressor (CDKN2A and BECN1) or tumor promoter (PRKCB) genes.
|
26510741 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined the immunohistochemical expression of autophagy-related proteins, microtubule-associated proteins light chain 3β (LC3), beclin-1, and p62/sequestosome-1 (p62), as well as tumor suppressor gene product p53.
|
25466963 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, the tumor volumes in subcutaneous nude mouse models in Beclin-1-deleted HOS cells were significantly smaller than those of control group.
|
25427639 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In ovarian cancer, prevalent mono-allelic deletion of BECN1 (a canonical autophagy-inducer) suggests that autophagy is impaired to promote carcinogenesis and that Beclin-1 is a haploinsufficient tumor suppressor.
|
26239434 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the hypoxic group, Beclin-1 expression was negatively correlated with HCC high tumor grade (p < 0.001), advanced stage (p = 0.013), large size (p = 0.002), and multifocal tumors (p = 0.047).
|
25596085 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, NS5ATP9-mediated autophagy is required for promotion of tumour cell growth, and this effect could be inhibited with 3-methyladenine, chloroquine or by Beclin 1-silencing.
|
25649430 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The impacts of Beclin 1 and Beclin 2 on autophagy and tumor growth were evaluated by conversion of LC3-I to LC3-II and by clonogenic assays, respectively.
|
26506105 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of Beclin 1 expression was observed in 38.3% (23/60) of the analyzed tumors.
|
26458502 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Beclin1 and LC3 were highly expressed in oncocytes of Hürthle cell tumors.
|
26354775 |
2015 |